Aarey Drugs Files SEBI Compliance Certificate for Q3 FY26
Aarey Drugs & Pharmaceuticals Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The filing confirms the processing of dematerialized securities by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
This is a standard regulatory filing regarding share dematerialization and does not involve any new business developments, financial results, or corporate actions that would significantly impact the company.
The announcement is a routine compliance filing and does not contain any information that would positively or negatively impact the company's stock or operations.
Aarey Drugs & Pharmaceuticals Limited has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, to the BSE Limited and the National Stock Exchange of India Limited. This certificate pertains to the quarter ended December 31, 2025.
The company received this confirmation from its Registrar and Share Transfer Agent, M/s. MUFG Intime India Private Limited. The certificate confirms that securities received from depository participants for dematerialization during the specified quarter were processed and confirmed with the depositories. It also states that the securities were listed on the stock exchanges where the company's existing securities are listed. Furthermore, the registrar confirmed that the security certificates received for dematerialization were duly verified, mutilated, cancelled, and the names of the depositories were substituted in the register of members within the prescribed timelines.
This submission is a routine compliance filing related to share transfer and dematerialization processes.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.